Aussie On-Demand Biomanufacturing Facility Unveiled

AusBiotech was proud to partner with the Translational Research Institute (TRI) for a BioBriefing event where we welcomed Queensland's Deputy Premier, the Hon Jarrod Bleijie MP, who announced the new name of the TRI's Australia-first on-demand cGMP biomanufacturing facility: ENTRI.

The name reflects TRI's ambitions of removing barriers for biomanufacturing in Australia – and enabling translation of medical science by creating an integrated pipeline from the laboratory bench, through clinical trials, to the bedside.

The Hon Jarrod Bleijie MP, Deputy-Premier of Queensland, made the announcement as part of a site visit, an innovation showcase and the AusBiotech Queensland BioBriefing event. The innovation showcase also featured presentations from TRI-based industry residents Microbio, AdvanCell [AusBiotech members], and EMVision.

ENTRI is proudly supported by the Queensland Government and TRI – and is due to be completed in early 2026.

The Deputy Premier acknowledged the importance of the facility to Queensland and Australia.

"ENTRI is ideally situated on the Princess Alexandra Hospital campus and within Brisbane's thriving Boggo Road Innovation Precinct, and will launch Queensland as the epicentre of biomanufacturing in Australia," he said.

"As part of the Queensland Government's re-focus on three new priority industries, including biomedical, I'm looking forward to seeing the industry development and innovation that will take shape at ENTRI and the broader precinct."

ENTRI will provide maturing, high-potential, biotech, pharma and medtech companies the environment and expertise to scale up manufacturing for clinical trials, while allowing them to retain their intellectual property.

It will feature Australia's first on-demand cGMP cleanrooms to advance development of a range of products, including RNA-based therapies, cell therapies, biologics, vaccines and drug-device combination products.

TRI CEO Professor Maher Gandhi says stakeholders are excited by the opportunity the facility provides to forge connections with government and regulatory bodies, industry and the research sector.

"We are confident our new capability will be attractive to international companies because it enables the integration of manufacturing with clinical trials in Australia, enabling internationals to take advantage of Australia's speed to the clinic and further reducing the overall cost of development programs through Australia's R&D Tax Incentive."

AusBiotech CEO Rebekah Cassidy has welcomed the ENTRI announcement, saying it sends a signal regarding the Queensland Government's ongoing commitment to strengthening critical capabilities and accelerating the scale-up of Australian health innovation.

"Australia's life sciences sector is thriving, with close to 1600 biotech and medtech companies nationwide. ENTRI will be a game-changer, enabling companies to scale and manufacture on home soil. We look forward to supporting the pipeline of innovation this investment will unlock."

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.